Prostate cancer is the leading cancer in men in Burkina Faso, contributing to an incidence rate of 26.3%, according to
GLOBOCAN 2020. Metastatic prostate cancer (mPC) makes up about 30% of prostate cancer cases. Our objective was to examine the epidemiological, diagnostic, and treatment characteristics of mPC hospitalized and non-hospitalized instances within the Clinical Oncology and Hematology Department of the University Hospital Center-Bogodogo (CHU-B). This study adopted a descriptive cross-sectional approach, encompassing retrospective data acquisition from May 1, 2017, to April 30, 2020. All patients undergoing follow-up for mPC, with confirmed histological diagnosis and metastatic verification supported by clinical, radiological, and/or histological evidence, were included. Data was collected from individual records within patients’ clinical files. mPC comprised 76.6% of the diagnosed prostate cancer cases. The average age was 67.7 years [range: 50 to 89 years]. The typical interval before consultation was 29.7 months. Urinary symptoms were present in 87.7% of cases, while bone pain was reported in 75.5% of cases. Secondary bone involvement was identified in 78.26% of instances. The mean total PSA level was 1179.28 ng/ml, [range: 7 to 9976 ng/ml]. The complete androgen blockade protocol was utilized for treatment in 69.3% of patients, with the Docetaxel protocol being employed in 26.5% of cases. The median survival duration was 8.13 months. mPC was predominant among prostate cancers, underscoring the urgency of promptly implementing Burkina Faso’s strategic plan for cancer control.

Metastatic Prostate Cancer CHU Bogodogo Burkina Faso Early Screening and Detection Treatment Characteristics